MAPT and Down syndrome: Our findings suggest that among adults with Down syndrome, cerebrovascular disease promotes Alzheimer’s disease-related neurodegeneration indirectly through increasing astrocytosis and tau pathophysiology in the preclinical stages of Alzheimer’s disease and directly and indirectly in the clinical stages of Alzheimer’s disease.